PD38-07 GENETIC CORRECTION OF PSA CAN REDUCE THE NUMBER OF MEN DIAGNOSED WITH POTENTIALLY INSIGNIFICANT PROSTATE CANCER: RESULTS FROM A SURGICAL AND ACTIVE SURVEILLANCE COHORT

Abstract

You have accessJournal of UrologyProstate Cancer: Detection and Screening III1 Apr 2015PD38-07 GENETIC CORRECTION OF PSA CAN REDUCE THE NUMBER OF MEN DIAGNOSED WITH POTENTIALLY INSIGNIFICANT PROSTATE CANCER: RESULTS FROM A SURGICAL AND ACTIVE SURVEILLANCE COHORT James Kearns, Brian Helfand, Kimberly Roehl, Kristian Novakovic, Phillip Cooper, and William Catalona James KearnsJames Kearns More articles by this author , Brian HelfandBrian Helfand More articles by this author , Kimberly RoehlKimberly Roehl More articles by this author , Kristian NovakovicKristian Novakovic More articles by this author , Phillip CooperPhillip Cooper More articles by this author , and William CatalonaWilliam Catalona More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2428AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES There is concern for an over-diagnosis of prostate cancer (PC). It is possible that genetic correction of PSA in men with seemingly indolent disease could adjust the PSA level below a biopsy threshold and avoid a PC diagnosis. METHODS The genotypes of 4 genetic variants previously associated with serum PSA levels (Sci Trans Med: 2010. 2; 62) were determined for Caucasian subjects with NCCN low- and very-low risk PC who underwent surgical treatment (898) and men with similar disease who enrolled in a prospective active surveillance study (147). The PC characteristics were documented for all subjects. Genetic correction of PSA was performed by dividing an individual's PSA value by his combined genetic risk. Analyses were used to compare the percentage of men who would meet commonly used biopsy thresholds before and after genetic correction. RESULTS Genetic correction of serum PSA was associated with a significantly decreased percentage of men meeting biopsy thresholds in the surgical cohort (p<0.001). Genetic correction was associated with a 23% and 27% relative reduction in the number of men meeting biopsy thresholds of ≥2.5 ng/ml and ≥4.0 ng/ml in the surgical cohort. Similar analyses in the AS cohort demonstrated that genetic correction could potentially reduce the number of biopsies and PC diagnoses by 39% and 40%. CONCLUSIONS Analyses of an independent and validated cohort suggest that a diagnosis of PC could have been avoided for a significant number of men with seemingly indolent PC if correction for 4 PSA genetic variants was applied prior to undergoing a prostate biopsy. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e827 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information James Kearns More articles by this author Brian Helfand More articles by this author Kimberly Roehl More articles by this author Kristian Novakovic More articles by this author Phillip Cooper More articles by this author William Catalona More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...